Arbutus Biopharma Corporation - Laporan Laba Rugi (TTM)

Arbutus Biopharma Corporation
US ˙ NasdaqGS ˙ CA03879J1003

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Arbutus Biopharma Corporation menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 6 7 8 8 10 11 21 33 36 39 33 24 22 18 13 10 7 6 6 15
Change (%) 12.50 9.00 10.81 21.76 8.06 95.27 55.52 7.83 8.45 -15.11 -28.95 -5.50 -18.43 -28.42 -22.52 -32.99 -8.47 3.76 140.76
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 45 49 53 58 63 66 70 77 81 84 84 79 79 74 71 40 34 54 48 53
Change (%) 8.76 6.82 10.12 8.00 4.50 7.14 10.18 4.33 4.63 -0.22 -6.23 0.14 -6.81 -3.90 -43.68 -14.78 58.95 -11.93 10.95
% of Revenue 738.11 713.60 699.36 694.98 616.46 596.12 327.10 231.73 224.21 216.33 254.25 335.55 355.58 406.26 545.42 396.51 504.26 875.66 743.29 342.54
Gross Operating Profit -39 -42 -45 -50 -53 -55 -49 -44 -45 -45 -51 -55 -57 -56 -58 -30 -27 -48 -41 -37
Change (%) 8.17 6.47 10.00 5.69 3.81 -10.62 -9.79 1.67 1.56 12.57 8.49 2.54 -2.26 4.11 -48.43 -8.64 75.62 -13.95 -9.23
% of Revenue -638.11 -613.60 -599.36 -594.98 -516.46 -496.12 -227.10 -131.73 -124.21 -116.33 -154.25 -235.55 -255.58 -306.26 -445.42 -296.51 -404.26 -775.66 -643.29 -242.54
SG&A 13 15 15 16 16 17 18 19 18 18 18 19 22 22 22 24 22 26 26 22
Change (%) 13.66 2.19 6.01 0.73 5.78 5.92 3.98 -3.66 -1.91 3.70 4.22 12.19 3.94 -1.07 7.05 -5.48 14.81 2.01 -16.01
% of Revenue 212.51 214.71 201.30 192.58 159.32 155.95 84.59 56.56 50.53 45.71 55.83 81.90 97.22 123.89 171.22 236.58 333.68 418.54 411.49 143.55
R&D 29 29 -15
Change (%) 0.00
% of Revenue 286.19 427.08 -99.03
OpEx 60 64 67 73 77 83 88 96 99 102 103 98 101 96 93 92 85 80 74 60
Change (%) 6.22 4.97 8.53 5.84 6.78 6.89 8.90 2.76 3.43 0.46 -4.35 2.51 -4.50 -3.24 -0.62 -7.79 -6.36 -7.42 -19.30
% of Revenue 983.13 928.30 894.03 875.57 761.12 752.07 411.69 288.29 274.74 262.03 310.08 417.44 452.80 530.15 716.64 919.28 1,265.03 1,294.20 1,154.79 387.06
Operating Income -54 -57 -60 -65 -67 -72 -67 -63 -63 -63 -70 -75 -78 -78 -80 -82 -79 -74 -68 -44
Change (%) 5.51 4.49 8.24 3.79 6.59 -6.66 -6.05 0.07 0.56 10.07 7.36 5.03 -0.55 2.62 2.94 -4.71 -6.18 -8.35 -34.48
% of Revenue -883.13 -828.30 -794.03 -775.57 -661.12 -652.07 -311.69 -188.29 -174.74 -162.03 -210.08 -317.44 -352.80 -430.15 -616.64 -819.28 -1,165.03 -1,194.20 -1,054.79 -287.06
Interest Expense -4 -4 -4 -3 -3 -3 -3 -2 -2 -2 -1 -1 -1 -0 -0 -0 -0 -0 -0 -0
Change (%) -4.68 -6.71 -8.98 -9.16 -7.66 -9.31 -10.85 -14.42 -12.70 -17.84 -21.93 -34.60 -36.60 -33.55 -44.92 -10.12 -9.27 -11.68 -4.96
% of Revenue -68.47 -58.01 -49.65 -40.79 -30.43 -26.00 -12.08 -6.92 -5.49 -4.42 -4.28 -4.70 -3.26 -2.53 -2.35 -1.67 -2.24 -2.22 -1.89 -0.75
Net Income -71 -64 -66 -72 -72 -76 -76 -70 -69 -69 -70 -73 -75 -73 -74 -77 -77 -70 -77 -54
Change (%) -10.67 3.95 8.00 0.56 5.95 -0.81 -6.87 -2.26 0.89 0.83 4.14 3.48 -3.47 2.11 3.63 -0.50 -8.84 9.51 -29.15
% of Revenue -1,161.03 -921.97 -879.31 -856.96 -707.79 -693.91 -352.49 -211.09 -191.34 -178.01 -211.41 -309.89 -339.32 -401.57 -572.81 -766.20 -1,137.64 -1,133.04 -1,195.86 -351.92

Source: Capital IQ

Other Listings
GB:0SGC
DE:I9DN € 3.31
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista